AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Prothena Corporation plc
Video analysis: PRTA
All videosNo video analysis for this stock yet. Request one from our team.
News: PRTA
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference.
KMDA or PRTA: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $1.86 per share a year ago.
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena reported financial results for the second quarter and first six months of 2026 and provided business highlights.
Prothena (NASDAQ:PRTA) Share Price Passes Below 200-Day Moving Average – Time to Sell?
Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $9.46 and traded as low as $8.51. Prothena shares last traded at $8.75, with a volume of 647,643 shares trading hands. Wall Street Analyst Weigh In
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?
Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.
SRPT or PRTA: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Sarepta Therapeutics (SRPT) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?
Similar companies
-
Bicycle Therapeutics plc
BCYC
·
NASDAQ
Compare
-
4D Molecular Therapeutics, Inc.
FDMT
·
NASDAQ
Compare
-
Verastem, Inc.
VSTM
·
NASDAQ
Compare
-
Olema Pharmaceuticals, Inc.
OLMA
·
NASDAQ
Compare
-
Neumora Therapeutics, Inc. Common Stock
NMRA
·
NASDAQ
Compare
-
Corvus Pharmaceuticals, Inc.
CRVS
·
NASDAQ
Compare